This technology offers screening solution for four cancers, including breast, endometrial, cervical, and ovarian cancer
CORE Diagnostics has announced its collaboration with PredOmix Technologies to launch OncoVeryx-F, multi-cancer detection test specifically designed for high-risk and asymptomatic women.
OncoVeryx-F identify cancer at stages 1 and 2. With an impressive accuracy rate of 98 per cent, OncoVeryx-F can detect the presence or absence of cancer and accurately identify the Tissue of Origin (TOO) in a single test. This technology offers screening solution for four cancers, including breast, endometrial, cervical, and ovarian cancer.
Dinesh Chauhan, CEO, CORE Diagnostics said, “We are thrilled to collaborate with PredOmix Technologies to bring OncoVeryx-F to the market. This ground-breaking multi-cancer detection test represents a significant advancement in early-stage cancer diagnosis. By combining the expertise of PredOmix with our commitment to improving patient outcomes, we aim to make a tangible difference in the lives of women at high risk for cancer.”
Dr Kanury V S Rao, Co-Founder and Chief Scientific Officer, PredOmix said, “OncoVeryx-F is a simple blood test that looks for cancer metabolic signatures in the bloodstream. This test is very significant for women. We have developed this test for early detection, so we can diagnose cancer earlier and so treatment can begin earlier and avoid some of the long-term problems and help women live longer. Together with CORE Diagnostics, we aim to reduce the number of advanced cancers in the country.”